Whereas these findings provide evidence for the safety and efficacy of targeting 12-LOX in the context of T1D, they leave unclarified the specific cell of action and molecular mechanisms of 12-LOX. This evidence concerns the gene ALOX12 and type 1 diabetes mellitus.